GW-501516 Powder Pharmaceutical Grade SARMs Cardarine CAS 317318-70-0 For Fat Loss

GW-501516（Cardarine）Specification

Product name: GW501516 (cardarine)
Alias: GSK-516
CAS: 317318-70-0
M.F.: C21H18F3NO3S2
M.W.: 453.5
M.P.: 134-136°C
Appearance: white solid
Usage: It had been investigated as a potential treatment for obesity, diabetes, dyslipidemia and cardiovascular disease. GW501516 could be used by athletes as an ergogenic performance enhancing drug.

GW-501516
GW-501516 is a unique medication officially classified as a PPAR receptor agonist (PPAR-RA). Research for this medication began in 1992 in a conjoined effort between GlaxoSmithKline (GSK) and Ligand Pharmaceuticals. Research into this product was set forth in an effort to provide treatment for various cardiovascular diseases, as well as diabetes, obesity and other conditions. It was soon discovered that the PPAR-RA was highly effective at enhancing endurance, but it was also shown to carry a high potential cost. It was discovered that GW-501516 increased the chances of cancer significantly, and as a result, GSK dropped all further research. However, the studies that produced cancerous results used doses of GW-501516 that were 500 to even 1000 times the amount that a human being would take. If cancer is a risk with standard dosing is unknown.

GW-501516（Cardarine）Application

There are two main uses with GW-501516. The first and most common use is that of increased endurance. GW has been banned for professional athletes due to the unfair advantage it provides to endurance athletes. Anyone want a drastic increase in endurance will find that GW truly shines in this aspect. It takes effect very quickly and the results can be staggering. A common dose of 10 mg day will provide a significant increase in endurance.

The second common usage with GW is that of fat loss. Many users turn to GW as it has shown to melt off fat while still being non-catabolic. You will find that you can still hold on to some muscle as you are losing fat. It helps when you are running it in conjunction with SARMS Ostarine and S4, to hold on to as much muscle as possible.

GW-50156 regulates fat burning through a number of widespread mechanisms; it increases glucose uptake in skeletal muscle tissue and increases muscle gene expression, especially genes involved in preferential lipid utilization. This shift changes the body’s metabolism to favor burning fat for energy instead of carbohydrates or muscle protein, potentially allowing clinical application for obese patients to lose fat effectively without experiencing muscle catabolism or the effects and satiety issues associated with low blood sugar. GW-501516 also increases muscle mass, which improved glucose tolerance and reduced fat mass accumulation even in mice fed a very high fat diet, suggesting that GW-501516 may have a protective effect against obesity.